Go or no go? Big decisions for Acelrx, Trevena, Loxo and Astellas
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.
Viking squares up to Madrigal
It’s time for Viking, a Nash player that has climbed in tandem with one of its biotech peers, to prove itself.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.